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CytokinesBenign prostatic hyperplasia (BPH) commonly occurs in older men with chronic prostatitis. Although BPH is
frequently accompanied by inﬂammation, it is unclear whether inﬂammation underlies prostate enlarge-
ment. Recently, we reported that hypoxia‐inducible factor 1α (HIF-1α), which is known to be induced by
proinﬂammatory cytokines, is involved in testosterone-induced prostate hyperplasia. Therefore, we hypoth-
esized that cytokines secreted from inﬁltrated macrophages under inﬂammatory conditions stimulate pros-
tate enlargement by up‐regulating HIF-1α. In the present study, we injected lipopolysaccharide (LPS) into rat
prostates to mimic prostatitis and evaluated prostate hyperplasia 14 days later. Epithelial cells of LPS-treated
prostates were found to be highly proliferative and HIF-1α levels in prostate tissues to be elevated. When
prostate epithelial cells were incubated in conditioned medium from macrophages activated with LPS, they
robustly expressed HIF-1α, and under these conditions IL-1β, IL-6, and TNF-α cytokines were found to
mediate HIF-1α induction. In addition, HIF-1α was found to enhance the expression of Twist, which initiates
epithelial–mesenchymal transition (EMT). Furthermore, profound EMT features were observed in
LPS-treated rat prostates, and the natural HIF-1α inhibitors ascorbate and curcumin were found to attenuate
EMT and prostate hyperplasia both in vivo and in vitro. Based on these results, we propose that HIF-1α me-
diates prostate enlargement under inﬂammatory conditions, and we suggest that HIF-1α be viewed as a
promising target for blocking the transition from prostatitis to BPH.
© 2012 Elsevier B.V. All rights reserved.1. Introduction
Benign prostatic hyperplasia (BPH) is one of the most common
chronic diseases in the male population. Its incidence gradually in-
creases with age, and about 50% of men aged over 50 suffer from BPH
symptoms, such as, urinary urgency, and retention [1]. Histologically,
BPH tissues are remodeled toward epithelial and stromal hyperplasia
due to an imbalance between cell proliferation and death [2]. Because
the prostate grows under the inﬂuence of androgen hormones,
5α-reductase inhibitors, which block activation process of testosterone,
are widely used to treat BPH [3,4]. Other than the androgen inhibition,
diverse therapeutic modalities are needed to realize the tailor-made
therapy for BPH patients.
Hypoxia-inducible factor 1 (HIF-1) is a transcription factor com-
posed of HIF-1α and HIF-1β subunits, and is a key player in hypoxiceoulNational University College
public of Korea. Tel.: +82 2 740
rights reserved.response [5]. The expression and activity of HIF-1α, but not of HIF-1β,
are tightly controlled under normoxic conditions, wherein HIF-1α is
prolyl-hydroxylated, recruits the pVHL-containing E3 ubiquitin ligase
complex, and then degraded via the ubiquitin–proteasome system.
Accordingly, when this hydroxylation is inhibited under hypoxic condi-
tions, HIF-1α is stabilized and activated [6–9]. Inﬂammation is another
microenvironmental factor that can stimulate HIF-1 signaling. When
tissues are inﬂamed, inﬁltrating immune cells and resident stromal
cells secrete a variety of cytokines, and some of which enhance
HIF-1α expression [10]. Subsequently, HIF-1α enters nuclei, where it
in association with HIF-1β binds to the hypoxia response elements
(HRE) of genes. Functionally, HIF-1α is amaster factor that orchestrates
the expressions of about 80 genes and determines cell fate under
hypoxic or inﬂammatory conditions [11]. In addition, HIF-1α drives
epithelial–mesenchymal transition (EMT) by inducing the expressions
of EMT-promoting transcription factors like Twist and Snail, and partic-
ipates in tissue remodeling by inducing enzymes degrading or modify-
ing extracellular matrix [12].
Recently, HIF-1α was found to be induced in prostate epithelial
cells by zinc ion and to help prostate cells survive in a zinc-rich
Fig. 1. LPS induces prostate hyperplasia, which is recovered by HIF-1 inhibition. (A) Ex-
perimental protocol. Rats were treated with LPS or HIF-1α inhibitors at the indicated
time points. (B) On the 14th day after the ﬁrst injection of LPS, prostates were excised
and weighed. C, PBS control; L, LPS alone; L+Asc, LPS plus ascorbate; L+Cur, LPS plus
curcumin. (C) Microscopic ﬁndings of prostates. Prostate tissues were ﬁxed, embedded
in parafﬁn, and sectioned at 4 μm. Sections were stained with hematoxylin and eosin,
and examined at a 400X magniﬁcation (top). Epithelial cell layer areas in the slides
were analyzed using ImageJ1.36b image analysis software (NIH, USA) (bottom). (D) In
prostates excised on the 3rd day after LPS injection, macrophages were immunostained
and their number was counted under a microscope. (E) PCNA was immunostained in
prostates excised on the 14th day after LPS treatment. PCNA positivity was evaluated
when the nuclear density versus the background density was more than 5 fold. The
right panel presents PCNA-positive cell numbers per 100 cells. (F) Apoptotic cell death
was analyzed by TUNEL staining (left). Results are presented as TUNEL-positive cell num-
bers per 100 cells (right). Arrows indicate representative cells with positive signal. Each
horizontal bar represents the mean value of 8 samples, and * denotes pb0.05 between
two groups.
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prolyl-hydroxylation process and consequently stabilizes HIF-1α
[13], which facilitates the expression of survivin that promotes cell
survival and proliferation [14]. HIF-1α has also been found to mediate
testosterone-induced hyperplasia in the rat prostate [15]. In line with
its malignant tumor promoting action, HIF-1α is involved in the path-
ogenesis of BPH, which exhibits features of benign tumors.
Androgens are known to enlarge the prostate and aggravate the
symptoms of BPH, but the incidence of BPH is markedly greater in
older men whose androgen levels decline with age [16,17]. This sug-
gests that local factors other than circulating sex hormones contribute
to the progress of BPH. Evidence accumulated over the last decade
supports the notion that intraprostatic inﬂammation predisposes
prostate to overgrow. In fact, inﬂammatory signs are usually detected
in BPH specimens [18]. Furthermore, it has been suggested in several
epidemiological studies that inﬂammatory reactions are involved in
the pathogenesis of BPH and in the aggravation of its clinical symp-
toms. Bacterial and viral infections, autoimmune response against
prostate antigens, hormonal imbalance, urinary reﬂux into the pros-
tate, and other mechanisms have been proposed to trigger
intraprostatic inﬂammation [19,20], and several proinﬂammatory cy-
tokines, such as, interleukins, TNF-α, and interferon-γ have been
suggested to mediate prostate enlargement under inﬂammatory con-
ditions [21–23]. These cytokines are believed to be produced by stro-
mal and immune cells, and to stimulate prostate cell proliferation in a
paracrine manner. However, the identities of the key mediators of
prostate cell proliferation under inﬂammatory conditions remain
open, though it is evident that their identiﬁcations might provide
new treatments for BPH.
In the present study, we explored the possible connection be-
tween inﬂammatory signaling and HIF signaling during BPH progres-
sion. More speciﬁcally, we investigated the validity of a hypothetical
mechanism underlying inﬂammatory BPH, namely, macrophage→
cytokines→HIF-1→excessive prostate enlargement. In addition, we
examined whether this mechanistic axis drives prostate tissue re-
modeling via EMT under inﬂammatory conditions. Accordingly, we
injected LPS into rat prostates to induce the transition from prostatitis
to BPH, and incubated normal prostate cells with conditioned media
obtained from LPS-activated macrophages with the aim of identifying
molecular entities associated with inﬂammation and hyperplasia.
Furthermore, we treated with HIF-1 inhibitors both in vivo and
in vitro to investigate the pathogenic role played by HIF-1 in inﬂam-
matory BPH.
2. Materials and methods
2.1. Materials
LPS, sodium ascorbate, curcumin, and anti-Vimentin Cy3 were
purchased from Sigma-Aldrich (St. Louis, MO). Culture media, fetal
bovine serum, Lipofectamine RNAimax, and Lipofectamine LTX-Plus
were from Invitrogen (Carlsbad, CA). Anti-HIF-1α antiserum was
generated in rabbits using a bacterially expressed fragment
containing amino acids 418–698 of human HIF-1α [24]. Anti-VEGF
and β-tubulin were obtained from Santa Cruz Biotechnology (Santa
Cruz, CA), and anti-Vimentin, p-PKCα/β, p-mTOR, mTOR, p-JNK,
JNK, p-ERK, ERK, p-AKT and AKT were from Cell Signaling Technology
(Danvers, MA). Anti-E-cadherin, anti-IL-1β, anti-IL-6, and TNF-αwere
from BD (San Jose, CA), and anti-LYVE-1 was from Biotechnology
(Billerica, MA).
2.2. The animal model
Male Sprague–Dawley rats (10 weeks age) were obtained from
Orient Bio (Gueong-Gi Province, South Korea). All animal procedures
were performed in accord with the Seoul National UniversityLaboratory Animal Maintenance Manual. Animals were anesthetized
with isoﬂurane, and the lower abdomen was incised to expose pros-
tates. Brieﬂy, PBS (100 μl) or LPS (100 μg/kg) was injected equally
into the right and left prostate lobes in the control (C; n=8) and
LPS groups, respectively. LPS-treated rats were divided into three
groups, and intraperitoneally injected with PBS (L group, n=8),
100 mg/kg of ascorbate (L+Asc group, n=8), or 120 mg/kg of
curcumin (L+Cur group, n=8). Rats were treated with LPS twice
one week apart and with the indicated drugs three times a week for
2 weeks. On the 14th day after the ﬁrst LPS injection, rat prostates
were excised, weighed, and used for the experiments. The experi-
mental protocol is illustrated in Fig. 1A.
2.3. Cell culture
PNT2 (a human prostate epithelium cell) and LNCaP (a human
prostate cancer cell) were obtained from ECACC (London, UK).
LNCap cells were cultured in RPMI-1640 medium supplemented
with 10% heat-inactivated fetal bovine serum, L-glutamine (2 mM),
HEPES (10 mM), penicillin and streptomycin; PNT2 cells were
maintained in RPMI1640 medium containing 10% heat-inactivated
fetal bovine serum in 5% CO2 at 37 °C.
Fig. 1 (continued).
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The sequence of the siRNA targeting HIF-1α (NM_001530) was
5′-AGUUAGUUCAAACUGAGUUAAUCCC-3′, corresponding to nucleo-
tides 360–384 in its coding region, and that of the control siRNA
was 5′-CAAGACCCGCGCCGAGGUGAAUU-3′. siRNAs were transfected
into cells using Lipofectamine RNAimax. Cells were stabilized for
48 h before experiments.2.5. Reporter assay
Luciferase reporter plasmid (a kind gift of Dr. Eric Huang at the
University of Utah) containing the rat VEGF promoter (−1947 to −1
from the transcription site)was co-transfectedwith the CMV-β-gal plas-
mid using Lipofectamine LTX-Plus reagent. Luciferase activities were
measured using a Lumat LB9507 luminometer (Berthold Technologies,
Bad Wildbad, Germany), and β-gal activity was measured to normalize
transfection efﬁciencies.2.6. RT-qPCR
Total RNAs from cells were isolated using Trizol reagent, and re-
verse transcribed at 46 °C for 20 min. Real time PCR was performed
using primers speciﬁc for human VEGF (5′-CGTGTACGTTGGTG
CCCGCT-3′, 5′-CCGCTCTGAGCAAGGCCCAC-3′), human CA9 (5′-TATG
AGGGGTCTCTGACTACA-3′, 5′-TTCTCATCTGCACAAGGAAC-3′), PDK1
(5′-GGTGAAGTTCATGGATGTCT-3′, 5′-TCTGCATTCACATTTGTTGT-3′),
LOX (5′-AGGGGTAGGGAGTTGGAGCGG-3′, 5′-CCTAAACGTCAGCAGG
CGACGG-3′), TWIST (5′-AGCTACGCCTTCTCGGTCT-3′, 5′-CCTTCTC
TGGAAACAATGACATC-3′) and 18S (5′TTCGTATTGCGCCGCTAGA-3′,
5′-CTTTCGCTCTGGTCCGTCTT-3′). To evaluate relative gene expres-
sions, quantitative real-time PCR was performed using an Applied
Biosystems StepOne Real Time PCR System and SYBR Green
JumpStart Tag ReadyMix qPCR kit, according to the manufacturers' in-
struction. mRNA quantiﬁcation was calculated using a standard curve,
which shows a reliable linearity (correlation coefﬁcient>0.98) and
an ampliﬁcation efﬁciency (90–110%). Each expression level of sam-
ples was normalized to the 18S RNA level.
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Total proteins were separated using 8–15% SDS/polyacrylamide
gels and transferred to Immobilon-P membranes and blocked with
5% nonfat milk in TTBS for 30 min. The membranes were then se-
quentially incubated with anti-LYVE-1, anti-HIF-1α, anti-E-cadherin,
anti-Twist, anti-Vimentin (diluted 1:1000 in 5% nonfat milk, over-
night at 4 °C) and the secondary antibodies conjugated with horse-
radish peroxidase (diluted 1:5000 in 5% nonfat milk, 1 h at room
temperature). Immune complexes were visualized using the en-
hanced chemiluminescent-plus reagent (GE Healthcare Bio-Sciences,
Piscataway, NJ).2.8. Immunoﬂuorescence analysis
Cells were rinsed in phosphate-buffered saline (PBS), ﬁxed with
3.7% paraformaldehyde for 15 min, permeabilized with 0.5% Triton,
and washed in PBS. Non-speciﬁc sites were blocked with 1% goat
serum for 30 minutes and the cells were incubated with the primary
antibodies diluted (1:100) in PBS overnight at 4 °C. Vimentin
was stained with anti-Vimentin Cy3 antibody (1:100) without a
secondary antibody. For staining E-cadherin, cells were sequentially
incubated with anti-E-cadherin antibody (1:100) and Alexa488-
conjugated anti-mouse antibody (1:200) (Invitrogen). Finally, cells
were mounted under coverslips on glass slides.Fig. 2. LPS induces HIF-1α and VEGF expressions. (A) HIF-1αwas immunostained in prostat
the nuclear density versus the background density exceeded two fold, the cell was regarded a
per 100 cells. (B) VEGF protein levels were analyzed in prostate tissue homogenates. Protein
of VEGF and α-tubulin were analyzed using ImageJ 1.36b. The ratios of VEGF to α-tubulin ar
and * denotes pb0.05 between two groups.2.9. Cytokine measurements
Human cytokines (IL-1β, IL-4, IL-6, and TNF-1α) were detected
using the Multiprex MAP Cytokine/Chemokine kits provided by
EMD Millipore (Billerica, MA).
2.10. Immunohistochemistry
Excised prostates were ﬁxed with formalin and embedded in
parafﬁn. Serial sections (4 μm) were cut from each parafﬁn block,
deparafﬁnized, rehydrated in a graded alcohol series, heated in
10 mM sodium citrate (pH 6.0) using microwave for 5 min to retrieve
antigens. The sections were then incubated with blocking solution
and incubated overnight at 4 °C with anti-HIF-1α (1:100), anti-
PCNA (1:100), anti-E-cadherin (1:500), anti-vimentin (1:100), and
anti-LYVE-1(1:200) antibodies. After incubation with secondary anti-
bodies (1:400) at room temperature for 1 h, the sections were visual-
ized with ABC kit (VECTOR Laboratories LTD; Burlingame, CA) and
DAB kit (DAKO; Denmark).
2.11. Statistics
All data were analyzed using Microsoft Excel 2007 software. The
Mann–Whitney U test (http://vassarstats.net/utest.html) was to de-
termine the signiﬁcance of differences, and all comparisons weree tissues which had been treated with LPS and/or HIF-1α inhibitors for 2 weeks. When
s being HIF-1α positive (arrow). The right panel presents HIF-1α positive cell numbers
s (40 μg) were subjected to immunoblotting (left panel), and the protein band densities
e plotted in the right panel. Each horizontal bar represents the mean value of 8 samples,
187H.-J. Kim et al. / Biochimica et Biophysica Acta 1832 (2013) 183–194two sided. Results are expressed as means and standard deviations,
and difference was considered signiﬁcant when P-value was less
than 0.05.
3. Results
3.1. LPS induces prostate hyperplasia, which is prevented by HIF-1
inhibitors
To induce inﬂammatory BPH, we injected a LPS solution into rat
prostates, and excised the prostates 2 weeks after the ﬁrst injections
(Fig. 1A). Rat prostates were signiﬁcantly enlarged after the LPS injec-
tion. To examine the role of HIF-1 in inﬂammatory BPH, we chose two
HIF-1 inhibitors, ascorbate and curcumin, because they are clinicallyFig. 3. LPS-activated macrophages indirectly induce HIF-1α in prostate cells. (A) HIF-1α in
cells. CM was obtained from THP-1 cells differentiated by 10 ng/ml of PMA, and Act-CM f
for 48 h. Prostate cells (PNT2 and LNCaP) or non-prostate cells (A549, HeLa, and MCF-7)
Western blotting for HIF-1α. To verify the cellular response to hypoxia, cells were in
(B) Time-dependent induction of prostate HIF-1α by Act-CM. PNT2 and LNCaP cells were tre
of HIF-1α inhibitors on Act-CM-induced HIF-1α expression. PNT2 cells were treated with
5 μM) for 3 h. (D) Act-CM activation of the VEGF promoter. PNT2 cells were co-transfecte
treated with Act-CM, Act-CM plus 40 μM ascorbate or 5 μM curcumin for 16 h, and lysed for
the means±SDs (n=4) of luciferase activities. (E) Act-CM expression of VEGF mRNA. PNT2
RNAimax reagent. After stabilized for 24 h, cells were treated with Act-CM for 24 h. Total
RT-qPCR. * denotes pb0.05 between two groups.applicable as natural products. Ascorbate and curcumin tended to re-
duce the weight of prostates enlarged by LPS, but not signiﬁcantly
(Fig. 1B). To conﬁrm prostate enlargement by LPS, we histologically
reviewed H&E-stained prostate sections. Structurally, the prostate
is composed of epithelia, stroma, and ﬂuid-ﬁlled lumens. In
LPS-treated prostates, epithelia were markedly thickened and folded,
and stromal cells were increased. Interestingly, epithelial thickness
was noticeably different among the three treatment groups
(L, L+Asc, and L+Cur), but lumen size was not (Fig. 1C, top). Areas
of epithelial layers are shown in the bottom panel of Fig. 1C. Unlike
prostate weight, epithelial thickening was signiﬁcantly prevented by
ascorbate or curcumin, suggesting that HIF-1 inhibitors prevent epi-
thelial cell proliferation in LPS-induced BPH. To conﬁrm LPS-induced
inﬂammation, we immunostained macrophages inﬁltrating prostatesduction in prostate cells by the conditioned media obtained from LPS-activated THP-1
rom THP-1 cells which were differentiated by PMA and activated by 10 ng/ml of LPS
were treated with LPS, CM, or Act-CM for 3 h, and the cell lysates were subjected to
cubated under normoxic (N, 20% O2) or hypoxic (H, 1% O2) conditions for 8 h.
ated with Act-CM for the indicated times, and subjected to Western blotting. (C) Effects
Act-CM or co-treated with Act-CM and ascorbate (20 and 40 μM) or curcumin (2 and
d with VEGF promoter–luciferase plasmid and β-gal plasmid and incubated for 24 h,
luciferase assay. Luciferase activities were normalized to β-gal activity. Bars represent
cells were transfected with 100 nM Si-HIF-1α or Si-control (Con) using Lipofectamine
RNAs were extracted from the cells and VEGF mRNA and 18S RNA were analyzed by
188 H.-J. Kim et al. / Biochimica et Biophysica Acta 1832 (2013) 183–194(Supplemental Fig. 1). It was found that macrophage numbers were
about three times greater in the LPS group than in the control
group, but these numbers were not reduced by ascorbate or curcumin
(Fig. 1D). This suggests that the anti-proliferative effects of ascorbate
and curcumin are irrelevant to their anti-inﬂammatory actions. To
further evaluate LPS-induced epithelial enlargement, we checked
markers of cell proliferation and apoptosis. PCNA (a proliferation
marker) or TUNEL (an apoptosis marker) positive cell numbers
were signiﬁcantly higher and lower, respectively, in LPS-treated pros-
tates. Furthermore, ascorbate and curcumin both prevented these
marker changes induced by LPS (Fig. 1E and F).
3.2. HIF-1α and VEGF were up-regulated in LPS-treated prostates
Previously, we reported that HIF-1α promotes the survival of pros-
tate epithelial cells and that it is involved in testosterone-induced
prostate hyperplasia [15]. These ﬁndings encouraged speculation
that HIF-1α plays a role in LPS-induced prostate hyperplasia. As wasFig. 4. HIF-1α protein is stabilized in Act-CM. (A) HIF-1α protein synthesis. PNT2 cells were
HIF-1α, washed, and treated with MG132 with or without Act-CM for the indicated times
stability. PNT2 cells were incubated under hypoxic conditions with or without Act-CM for
and β-tubulin levels were analyzed by Western blotting (left). Band intensities were qu
decay curves (right). (C) Act-CM activation of signaling pathways. PNT2 cells were incubated
of phospho-AKT (p-AKT), AKT, phospho-mTOR (p-mTOR), mTOR, phospho-ERK (p-ERK),
(D) Effects of protein kinase inhibitors on Act-CM-induced HIF-1α. PNT2 cells were transfecte
inhibitors for 3 h C, control; G, 200 nMGO6976 (PKC inhibitor); L, 25 μM LY294002 (PI3K inhi
SP600125 (JNK inhibitor). Cellular levels of indicated proteins were evaluated by Western bloexpected, HIF-1α expression was substantially induced in the nuclei
of epithelial cells in LPS-treated prostates, whereas it remained at
the basal level in ascorbate or curcumin‐treated rats (Fig. 2A). We
checked VEGF levels because VEGF is expressed by HIF-1 and acts as
a key player in tissue remodeling [14]. Prostate VEGF protein was
found to be induced HIF-1-dependently by LPS (Fig. 2B), suggesting
that the HIF-1/VEGF axis participates in the prostate enlargement
induced by LPS.
3.3. HIF-1α in prostate cells is induced by LPS-activated macrophage
conditioned medium
To understand how LPS stimulates the HIF-1 signaling pathway, we
treated prostate cells with LPS or with the conditioned medium from
macrophages. In two prostate cell lines (PNT2 and LNCaP), HIF-1α
was not induced directly by LPS, but was expressed even under
normoxic conditions in the conditioned medium (CM) obtained from
THP-1 macrophages (Fig. 3A, top). Interestingly, HIF-1α expressiontreated with 100 μM cycloheximide (CHX) for 1 hour to block the de novo synthesis of
. Synthesized HIF-1α protein was monitored by Western blotting. (B) HIF-1α protein
8 h and then supplied with 20% oxygen for the times indicated in the ﬁgure. HIF-1α
antiﬁed using ImageJ. Half-lives (t1/2) were calculated from the slopes of ﬁrst-order
with Act-CM for the indicated times and harvested for Western blotting. Protein levels
ERK, phospho-JNK (p-JNK), JNK, and β-tubulin were evaluated by Western blotting.
d with HA-tagged HIF-1α plasmid and then treated with Act-CM with or without various
bitor); R, 1 μMRapamycin (mTOR inhibitor); P, 50 μM PD98059 (ERK inhibitor); S, 10 μM
tting.
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(Act-CM). In contrast, three non-prostate cells did not express HIF-1α
in Act-CM (Fig. 3A, bottom) though they robustly induced HIF-1α
under hypoxia. Therefore, prostate cells seem to have a unique pathway
for theHIF-1α induction byAct-CM.HIF-1α expressionwas observed as
early as 4 h after Act-CM treatment and was maintained to 16 h
(Fig. 3B). Expectedly, ascorbate or curcumin inhibited Act-CM-induced
HIF-1α expression (Fig. 3C).We next analyzed the transcriptional activ-
ity of HIF-1 using the VEGF promoter–luciferase reporter system, and
found that VEGF promoter activity was enhanced by Act-CM, butFig. 5. Identiﬁcation of inﬂammatory cytokines in Act-CM. (A) Pro-inﬂammatory cytokin
Materials and methods. (B) PNT2 cells were treated with Act-CM which had been pre-inc
1 μg/ml), TNF-α (0.1 or 1 μg/ml) or IgG (0.1 or 1 μg/ml as a control) for 2 h. Cells were then h
IL-1β, IL-6, or TNF-1α at the indicated concentrations for 3 h and HIF-1α levels were analyrepressed by HIF-1 inhibitors (Fig. 3D). Furthermore, VEGF mRNA
level increased in Act-CM, which was abolished by HIF-1 inhibitors.
These results indicate that Act-CM expresses functional HIF-1α which
enables to transactivate the VEGF gene.
3.4. Act-CM stabilizes HIF-1α protein
To understand the mechanism underlying Act-CM-induced
HIF-1α expression, we ﬁrst examined which step HIF-1α is regulated
in. De novo synthesis of HIF-1α protein was not affected by Act-CMes in CM or Act-CM were quantiﬁed by ELISA kits. Details provided are described in
ubated with speciﬁc neutralizing antibodies to IL-1β (0.01 or 0.1 μg/ml), IL-6 (0.1 or
arvested, assayed byWestern blotting (left). PNT2 cells were treated with recombinant
zed by Western blotting (right).
Fig. 6. The HIF-1-targeted genes are activated by Act-CM. (A) Act-CM induces the
mRNAs of HIF-1-targeted genes. PNT2 cells were treated with Act-CM or co-treated
with Act-CM plus ascorbate or curcumin for 16 h, and then harvested. Total RNAs
were puriﬁed and mRNA levels of CA9, PDK1, LOX, Twist, and 18S were analyzed by
RT-qPCR. The mRNA levels are presented as relative values to the control levels. Each
bar represents the mean±SD of four separate experiments. *, pb0.05 versus the
control; #, pb0.05 versus the Act-CM alone. (B) Act-CM induces mRNA expressions
HIF-1-dependently. PNT2 cells were transfected with 100 nM Si-HIF-1α or Si-Con
using Lipofectamine RNAimax reagent. After stabilized for 24 h after transfection,
cells were treated with Act-CM for 24 h, and then harvested. Total RNAs were puriﬁed
and the mRNA levels were analyzed by RT-qPCR. Each bar represents the mean±SD of
four separate experiments, and * denotes pb0.05 between two groups.
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half-life of HIF-1α protein increased in Act-CM-treated cells over
three times versus untreated cells (Fig. 4B). Next, we sought to iden-
tify the signaling pathways activated by Act-CM, and found that
AKT, mTOR, ERK, and JNK were all activated (Fig. 4C). Of these signal-
ing pathways, which contributes to the HIF-1α stabilization by
Act-CM? To answer this question, we ectopically expressed HIF-1α
using the HA/HIF-1α plasmid. Since the plasmid contains no 5′UTR
of the HIF-1α gene, its product can be regulated only at the post-
translational level, but not at the translational level. The 5′UTR seg-
ment is known to mediate the HIF-1α protein synthesis triggered
by the PI3K/AKT/mTOR pathway. Expressed HIF-1α was found to be
stabilized by Act-CM, and of the kinase inhibitors examined, a JNK in-
hibitor showed the best effectiveness in abolishing the HIF-1α stabi-
lization by Act-CM (Fig. 4D).
3.5. HIF-1α is induced by pro-inﬂammatory cytokines released from
activated THP-1 cells
To identify the components in Act-CM responsible for HIF-1α in-
duction in PNT2 cells, we analyzed the cytokines included in
Act-CM. IL-1β, IL-6, and TNF-α levels were much higher in Act-CM
than in CM, but IL-4 level was not (Fig. 5A). To determine whether
these cytokines contribute to HIF-1α induction, antibodies neutraliz-
ing the cytokines were administered to Act-CM, and each antibody
was found to attenuate the HIF-1α induction by Act-CM. Moreover,
when PNT2 cells were treated with recombinant IL-1β, IL-6, or
TNF-α without Act-CM, HIF-1α levels increased dose-dependently
even under normoxia (Fig. 5B). The cytokines in Act-CM are likely
to stimulate HIF-1α expression in prostate epithelial cells. As ascor-
bate and curcumin did not affect the cytokine levels in Act-CM
(Supplemental Fig. 2), they are likely to directly control HIF-1α
expression in prostate epithelial cells, but not to suppress cytokine
production from macrophages.
3.6. HIF-1α drives EMT through Twist
SinceHIF-1αwasﬁrst puriﬁed in 1995 [25], 80 ormore genes down-
stream of HIF-1 have been identiﬁed. Accumulative evidence suggests
that HIF-1 plays divergent roles cell context-dependently. To gain a
better understanding of the role of HIF-1 in inﬂammatory BPH, we
examined gene expression proﬁles in PNT2 cells treated with Act-CM.
In RT-qPCR analyses, CA9, PDK1, LOX, and Twist mRNAs were
up-regulated by Act-CM (Fig. 6A), and the mRNA inductions were at-
tenuated byHIF-1α knock-down (Fig. 6B). These results further support
the functionality of Act-CM-induced HIF-1α. Unexpectedly, ascorbate
and curcumin did not equally repress the expressions of these genes
downstream of HIF-1. Although ascorbate signiﬁcantly repressed all of
the genes tested, curcumin only markedly affected Twist expression
(Fig. 6A). In view of the fact that the anti-BPH effect of curcumin was
found to be comparable to that of ascorbate (Fig. 1), it would appear
that not all genes downstream of HIF-1 are required to induce prostate
hyperplasia. Therefore, we focused on Twist suppression by ascorbate
and curcumin under the presumption that the HIF-1/Twist/EMT axis
drives prostate hyperplasia via tissue remodeling.
3.7. Prostate epithelial cells undergo EMT under inﬂammatory conditions
The representative feature of EMT is a coincidence of E-cadherin loss
and vimentin gain [26]. After PNT2 cells were incubated with Act-CM
for 24 or 48 h,we found the EMT feature by immunoﬂuorescence or im-
munoblotting (Fig. 7A). When HIF-1α was knocked-down, the EMT
marker modulations were not induced by Act-CM (Fig. 7B). We next
checked these modulations in rat prostate tissues (Fig. 7C). In normal
prostates, E-cadherin was expressed along epithelial cell boundaries,
but vimentin was not. However, in LPS-treated prostates, E-cadherinwas less expressed at hyperplastic zones, but continued to be expressed
at non-hyperplastic zones. Conversely, vimentin was highly expressed
at hyperplastic zones in LPS-treated prostates, but not at non-
hyperplastic zones. These ﬁndings suggest that epithelial hyperplasia
is associated with EMT in inﬂammatory BPH. However, the EMT feature
was not shown in ascorbate- or curcumin-treated prostates. These EMT
markers were also analyzed by immunoblotting in rat prostates. How-
ever, as EMT was localized only in hyperplastic zones, the EMT marker
modulations were not so much remarkable in whole tissue homoge-
nates as shown in immunohistochemistry (Fig. 7D). Given the mean
values of EMTmarkers, the immunoblotting results show the same ten-
dency to immunohistochemistry results though they are less signiﬁcant
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EMT HIF-1-dependently under the inﬂuence of inﬂammation and then
become hyperplastic, and that this pathologic process underlies the hy-
perplastic remodeling of prostates treated with LPS.
4. Discussion
Chronic inﬂammation is regarded to predispose BPH, and inﬂam-
matory cytokines may stimulate prostate enlargement [27]. However,
the mechanism underlying inﬂammatory hyperplasia of the prostate
has not been determined. In the present study, in rats with
LPS-induced prostate hyperplasia, prostate epithelial cells highly
expressed HIF-1α and VEGF. Furthermore, in cultured prostate cells,
HIF-1α was robustly induced by the conditioned medium from
LPS-activated macrophages. IL-1β, IL-6 and TNF-α were secreted
from macrophages and induced HIF-1α in prostate epithelial cells.
Moreover, Twist was up-regulated by HIF-1α and markers character-
istic of EMT were changed in prostate cells. These markers were also
signiﬁcantly changed in LPS-induced hyperplasic prostates. In addi-
tion, we further found that ascorbate and curcumin reduce HIF-1α
levels and prevent prostate EMT and hyperplasia in vivo and in vitro.
These results suggest that the HIF-1-drived EMT contributes to in-
ﬂammatory prostate hyperplasia.
Recently, we reported that HIF-1α participates in the survival and
proliferation of prostate cells [13–15]. HIF-1α is a key transcription
factor that governs the expressions of many hypoxia-induced genes,
which include erythropoietin, angiogenic factors, glycolytic enzymes,
and cell growth/survival factors. In the zinc-rich environment of the
prostate, HIF-1α is induced even under normoxic conditions [13].
Actually, the role of HIF-1α under normoxic conditions has attracted
attention because it is rarely expressed in normoxic environments. In
this respect, the prostate is an exceptional tissue that constitutivelyFig. 7. HIF-1α-dependent EMT in prostate cells and tissues. (A) The reciprocal expressions of E-
for the indicated times, E-cadherin (E-cad, green) and vimentin (Vim, red) levelswere assessed
Act-CM dependent expressions of HIF-1α, E-cadherin, and vimentin were analyzed by Weste
Act-CM. PNT2 cells were transfected with 100 nM siRNA of HIF-1α or control using Lipofecta
harvested, and subjected to immunoﬂuorescent staining (left). HIF-1α, E-cadherin, and vime
and Vim in the rat prostate tissues. Rats were treated with LPS alone or LPS plus HIF-1α inhib
immunohistochemistry (upper). C, PBS control; L, LPS alone; L+Asc, LPS plus ascorbate; L+Cu
of prostate tissues. Proteins (40 μg)were subjected toWestern blotting (upper), and the protei
or Vim to α-tubulin are plotted in the lower panels. Bars represent means±SDs (n=4), and *expresses HIF-1α. Functionally, HIF-1α promotes cell survival in the
prostate, which is mediated by the HIF-1-dependent expression of
survivin [14]. It has also been demonstrated that HIF-1α is up-
regulated by testosterone in the hyperplasic prostates of rats and in
cultured human prostate cells. As oxygen consumption increases
along increasing cell number, hyperplasic prostate tissues are more
prone to hypoxia than are normal tissues, which may further stimu-
late HIF-1α expression. Therefore, HIF-1α is considered to be posi-
tioned at the center of this BPH-provoking vicious cycle. Indeed,
ascorbate has been shown to prevent prostate enlargement by
deregulating HIF-1α in a BPH animal model [15]. These previous re-
ports and the present study consistently support the notion that
HIF-1α plays a positive role in the progression of prostate hyperpla-
sia, and suggest that HIF-1α is a potential therapeutic target for BPH.
Many small molecules inhibiting HIF-1 have been identiﬁed and a
few of them are processed for clinical application [28]. Although
HIF-1 is regarded as a valid target for cancer therapy, the HIF-1 target
therapy has not been established so far because no HIF-1 speciﬁc in-
hibitor was developed. Most of HIF-1 inhibitors express their activi-
ties indirectly by targeting some molecules that modulate HIF-1
expression or activity. Under this circumstance, we decided that clin-
ical applicability is more important in choosing HIF-1 inhibitors than
target speciﬁcity, and ﬁnally chose two natural products, ascorbate
and curcumin. To strengthen the mechanism study, we here used
siRNAs targeting HIF-1α in addition to these inhibitors.
BPH results from an imbalance between prostate cell growth and ap-
optosis, which is probably determined by systemic (hormonal) and local
factors. In addition, the intraprostatic microenvironment might provide
important local factors that affect prostate growth and differentiation
[29]. Of these local factors, inﬂammation is generally regarded to stimu-
late prostate enlargement, for example, many histological examinations
have shown that inﬂammatory cells inﬁltrate around hyperplasticcadherin and vimentin by Act-CM in PNT2 cells. After PNT2 cells were treatedwith Act-CM
by immunoﬂuorescent staining using anti-E-cadherin or anti-vimentin antibody (left). The
rn blotting using speciﬁc antibodies in PNT2 cells (right). (B) HIF-1α dependent EMT by
mineRNAimax reagent. After 48 h stabilization, cells were treated with Act-CM for 24 h,
ntin proteins were analyzed by Western blotting (right). (C) The expressions of E-Cad
itors (ascorbate or curcumin) for 2 weeks. E-cad and Vim expressions were evaluated by
r, LPS plus curcumin. (D) Tissue levels of E-Cad and Vim were measured in homogenates
n band densities of E-Cad, Vim, andα-tubulinwere analyzed using ImageJ. Ratios of E-Cad
denotes pb0.05 between two groups.
Fig. 7 (continued).
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miological studies support a relationship between prostate inﬂamma-
tion and hyperplasia. BPH with inﬂammation tends to be associated
with a larger prostrate volume and a poorer clinical course than
that without inﬂammation, and a large proportion of BPH patients
have been reported to have a history of chronic prostatitis [29,30].
Nonetheless, despite much clinical evidence, the cause–effect relation-
ship between inﬂammation and BPH remains unclear largely because
inﬂammatory prostate hyperplasia has not been appropriately
reproduced in an animalmodel. In the present study,we successfully in-
duced prostate hyperplasia in rats by injecting LPS into prostates, and
evaluated hyperplasia by gross inspection,microscopy, and immunohis-
tochemistry. Although we cannot argue that LPS treatment induces
clinical prostatitis, LPS does induce intraprostatic inﬂammation as
evidenced by inﬁltrations of many inﬂammatory cells into prostates.
Furthermore, the ﬁndings obtained from this animal model strongly
suggest that the transition from inﬂammation to hyperplasia could
occur in the prostate.
Because we directly injected a LPS solution into prostate tissues,
resident and inﬁltrating cells could have been stimulated. In additionto inﬁltrating inﬂammatory cells, prostate resident cells could be
involved in the priming and progression of inﬂammatory responses.
Indeed, prostate cells have been reported to express several types of
Toll-like receptors (TLR-4, -5, -7 and ‐9) and interleukins (IL-1 and
IL-15) in response to LPS stimulation [33–36]. For this reason, we
also treated prostate cells with LPS in a culture system, but did not
observe either the induction or activation of HIF-1α. In contrast,
HIF-1α expression and activity were noticeably induced by the condi-
tioned medium from LPS-activated macrophages. Furthermore, IL-1β,
IL-6, and TNF-α levels in conditioned medium were substantially
increased by treating macrophages with LPS, and neutralizing anti-
bodies against these cytokines attenuated HIF-1α induction by the
conditioned medium. In addition, by using recombinant peptides,
we conﬁrmed that all of these cytokines have HIF-1α-inducing activ-
ity in prostate cells, which strongly suggests that inﬁltrating inﬂam-
matory cells, rather than prostate resident cells, responded to LPS
and produced HIF-1α-inducing cytokines. Unfortunately, since im-
mortalized human prostate cell lines were used for this experiment,
we cannot exclude the possible participation of original prostate
cells in the production of these cytokines.
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During EMT, epithelial cells lose their adhesiveness, become more mo-
tile, and assume a spindle-shaped morphology reminiscent of mesen-
chymal cells. Epithelial cells undergoing EMT lose epithelial makers
like E-cadherin and cytokeratins but induce mesenchymal markers like
vimentin andα-smoothmuscle actin, and as a consequence, the epithe-
lial structure is reorganized toward tissue remodeling [26,37,38]. Micro-
environmental stress, such as hypoxia or inﬂammation, mainly drives
EMT, which is regarded an adaptive process to a stressful environment.
A growing body of evidence suggests that EMT is associatedwith a num-
ber of human diseases, such as, cancer progression, metastasis, and
hepatic ﬁbrosis in chronic liver diseases [39,40]. Yet, the relation be-
tween EMT and BPH has received little attention. Very recently, it was
demonstrated that an immortalized prostate cell line had the potential
to undergo EMT after treatment with TGF-β1 [41]. In another study,
epithelial regions in BPH specimens were found to be depolarized and
spindle-shaped [42]. It was also suggested that BPH is caused by an
accumulation of mesenchymal-like cells derived from prostatic epitheli-
um and endothelium because regions of ductal epithelium, in which
cells do not express E-cadherin, showed EMT characteristics. In the
present study, we found that EMT markers were changed in prostate
cells treated with the medium from LPS-activated macrophages and in
rat prostates treated with LPS. Therefore, we propose EMT drives
prostate tissue remodeling and that this partly contributes to prostate
hyperplasia under inﬂammation. Then, it could be askedwhatmediates
EMT in the inﬂamed prostate. Inﬂammatory cytokines can induce
EMT in cancerous and non-cancerous tissues through ERK, MAPK, p38,
or NF-kB signaling pathways [43–46]. In addition, HIF-1α is known
to be an EMT inducer, because it induces the expressions of EMT-
promoting transcription factors and of extracellular matrix-degrading
or -modifying enzymes [12,47,48]. Our results suggest that the JNK/
HIF-1/Twist pathway is involved in prostate EMT under inﬂammatory
conditions.
Regarding, the mechanism responsible for inﬂammatory BPH, we
propose that inﬂammatory cells recruited by the prostate secrete
cytokines which stimulate prostate cells to express HIF-1α, and that
this expression drives prostate remodeling toward hyperplasia.
Furthermore, we suggest that HIF-1α inhibition be viewed as a
novel means of preventing the progress of prostate hyperplasia due
to inﬂammation. We hope that this study sheds new light on the
pathogenesis of BPH, and that it aids those involved in the develop-
ment of anti-BPH drugs.
Supplementary data to this article can be found online at http://
dx.doi.org/10.1016/j.bbadis.2012.09.002.
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